Better Glycemic Control for Better Heart Health

This study on the “Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial” used data from the Trial Evaluating Cardiovascular Outcomes With Sitagliptin and found that sudden death was the most common subcategory of cardiovascular death. Results suggest that heart failure prevention may reduce the risk of such death, with the use of devices such as the implantable cardioverter defibrillator and improving glycemic control (Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6.)
 
As the principal investigator of the sole Asian site in this study, our key investigator Prof Juliana Chan welcomes anyone interested in future collaboration in this field of research. Prof Chan is the director of our Hong Kong Institute of Diabetes and Obesity and her research interest is in the epidemiology, genetics and care models of diabetes and obesity.
 
Read the full article: http://care.diabetesjournals.org/content/40/12/1763.long